To define a dynamic sequence of phenotypic changes related to early and late phases of NK-cell activation, we have analyzed by four-color flow cytometry the immunophenotype of normal blood NK-cells from 12 healthy individuals and compared it with those from 15 patients with acute viral infections and 15 patients with either chronic infections or tumors. Although a great interindividual variability was found, nonstimulated CD56 ϩ NK-cells, present in normal blood samples, usually were CD2
INTRODUCTION
Increased numbers of circulating NK-cells have been described in various physiological and pathological conditions (1) (2) (3) (4) , in addition to NKcell leukemias/lymphomas (5, 6) . In the former cases, they are believe to represent reactive cells that proliferate in response to a stimulus and that play an important role in host defense by exhibiting cytotoxicity against tumor and virus-infected cells, whereas in the latter case the malignant NK-cell population shows autonomous proliferation (7, 8) .
Several phenotypic changes have been shown to occur after "in vitro" stimulation of NK-cells, including acquisition of molecules that are not expressed on resting NK-cells and up-or downregulation of receptors that are constitutively expressed on this leukocyte population (9 -29) . Most of these molecules proved to have an important role in determining migration of NK-cells into tissues, as well as in regulating NK-cell proliferation, target cell recognition, conjugate formation, and effective killing. Nevertheless, information on the immunophenotypic changes occurring after NK-cell activa-tion "in vivo" is scanty and the few studies that have been published to date on this subject are restricted to the evaluation of a limited number of activation-related markers (30 -32) . The fact that blood NK-cells are heterogeneous (33) and that the typical immunophenotypic patterns observed in normal non-stimulated and stimulated NK-cells are far from being well-characterized, makes it difficult to distinguish between resting/activated normal polyclonal NK-cells and their neoplastic counterparts. Moreover, in the diagnosis of NK-cell leukemia/lymphoma molecular studies are not as useful as for T-and B-cell disorders-NK-cells do not rearrange the TCR genes and other alternatives such as Xlinked molecular analysis frequently are either not applicable or not available (34, 35) -imposing additional difficulties in distinguishing normal from neoplastic NK-cells. Therefore, in patients displaying persistent NK-cell lymphocytosis in the absence of an obvious underlying disease the assessment of NK-cell clonality still remains a challenge. A comparative study of the immunophenotypic properties of normal blood NK-cells versus those of blood NK-cells from patients with pathological conditions potentially associated to NK-cell activation would not only contribute to a better understanding of the biological changes occurring during NKcell activation, but it would also have immediate clinical application, since it could set the basis for the discrimination between normal and neoplastic NK-cells.
In view of this purpose, we have recently characterized the immunophenotypic profile of normal blood CD56 ϩlo and CD56 ϩhi NK-cell subsets in that concerning the expression of a number of functionally relevant receptors (36) . In the present paper we focus on the immunophenotypic changes occurring in vivo in conditions in which NK-cell activation is likely to occur, such as in patients with acute viral infection (AI) or in patients with chronic infection or neoplasias (CI/N) and compare the phenotypic patterns of blood CD56
ϩ NK-cells from these patients with those of normal healthy individuals.
MATERIALS AND METHODS

Patients and Controls
A total of 15 patients with acute viral infection irrespectively of having or not NK-cell lymphocytosis (8 males and 7 females, median age of 30 years, range: 11 to 58 years) and 15 patients with chronic infection or hematological neoplasias (11 males and 4 females, median age of 61 years, range: 11 to 83 years) in which persistent blood NK-cell lymphocytosis was an occasional finding in immunophenotypic studies performed as part of the investigation of the associated condition were studied.
All patients with acute infection had acute infectious mononucleosis due to recent EpsteinBarr virus (n ϭ 6), cytomegalovirus (n ϭ 5) or hepatitis C-virus (n ϭ 1) infection or infection of unknown origin (n ϭ 3). Among cases with chronic NK-cell lymphocytosis, four patients suffered from chronic infections, whereas the remaining 11 patients had an associated B-cell hematological disorder (non-Hodgkin lymphoma in 6 cases, Waldenstrom's macroglobulinemia in 1 case, multiple myeloma in 2 cases and monoclonal gammapathy of uncertain significance in the remaining 2 cases).
In addition, 12 normal healthy volunteers (blood donors)-7 males and 5 females aged from 24 to 48 years-were studied as controls. In all cases, samples were obtained after informed consent.
Immunophenotypic Studies
All studies were done in K3-EDTA anticoagulated blood samples. Immunophenotypic analyses were performed using a whole blood stain-lyse-and-then-wash direct immunofluorescence technique and four-color staining as previously described in detail (36) . PE-cyanine 5-conjugated anti-CD56 and allophycocyanin-conjugated anti-CD3 were used in combination with the following pairs of fluorescein isothiocyanate-/ phycoerythrin-conjugated monoclonal antibodies (MoAb) directed against T-and NK-associated antigens: CD2/CD7, CD57/CD11c, CD38/CD11b, CD11a/HLA-DR, CD45RA/CD45RO, CD7/CD5, CD16/NKB1, CD158a/CD161, and CD94/CD8. NK-cells from controls and CI/N individuals were characterized for the expression of all the markers described above whereas NK-cells from AI patients were studied only for the expression of CD2/CD7, CD57/CD11c, CD38/CD11b, CD11a/HLA-DR, CD45RA/CD45RO, and CD16/ NKB1.
The anti-CD3, -CD5, -CD8, -CD11b, -CD11c, -CD45RA, -CD45RO, -CD56, -CD57, -CD94, -CD158a, -CD161, -HLA-DR and -NKB1 reagents were purchased from Becton/Dickinson Biosciences (BD, San Jose, CA); the anti-CD7 and anti-CD16 MoAb were from Beckman Coulter (Miami, FL), anti-CD11a was from CLB (Amsterdam, The Netherlands) and anti-CD38 from Cytognos (Salamanca, Spain). Anti-CD7 was either from BC (PE) or from CLB (FITC) and anti-CD8 was from BD or from Dako A/S (Glostrup, Denmark).
Data acquisition was carried out for all samples in a FACSCalibur flow cytometer (BD) equipped with a 15-mW air-cooled 488-nm argon ion laser and a 625-nm neon diode laser, using the Cell QUEST software program (BD). Information on a minimum of 2 ϫ 10 5 events was acquired and stored as list mode data files for each staining. For data analysis the Paint-a-Gate PRO software program (BD) was used. In all samples analyzed, total NK-cells were firstly identified in the CD2/ CD7/CD56/CD3 tube by their positivity for CD2 and/or CD7 in the absence of reactivity for CD3, in order to calculate the percentage of NK-cells within the lymphocyte population, as well as to establish the distribution of the CD56 Ϫ , CD56 ϩlo and CD56
ϩhi NK-cell subsets in each case. Afterward, the phenotypic characterization of the major CD56
ϩlo NK-cell population for the remaining markers included in the study was performed after specifically selecting for the CD3 
Statistical Analysis
For all variables under study, mean, standard deviation, median and range values were calculated. The statistical significance of differences observed between groups was evaluated using the Mann-Whitney U test (SPSS 9.0., SPSS, Chicago, IL). P values less than 0.05 were considered to be associated with statistical significance.
RESULTS
The absolute number of total PB NK-cells was of 226 Ϯ 151 ϫ In each group, only a minority of NK-cells was considered to be either CD56 Ϫ (7 Ϯ 5, 8 Ϯ 4, and 6 Ϯ 4% in controls, AI, and CI/N patients, respectively; P Ͼ 0.05) or CD56 ϩhi (7 Ϯ 6%, 3 Ϯ 4% and 2 Ϯ 1% in controls, AI and CI/N patients, respectively; P Ͼ 0.05).
Patterns of Expression of CD2/CD7, CD57/ CD11c, CD11b/CD38, and CD11a/HLA-DR on CD56 ϩlo NK-Cells from Normal and Pathological Blood Samples
The immunophenotypic data obtained in normal individuals, AI patients and CI/N patients are summarized in Tables 1 and 2 . As may be seen in both tables, the vast majority of CD56 ϩlo NKcells from both controls and patients expressed CD7, although among CI/N patients the mean levels of CD7 expressed per cell were significantly lower (MFI of 991 Ϯ 446 in CI/N patients versus 1460 Ϯ 402 in controls and 1764 Ϯ 644 in AI patients, P Ͻ 0.01) and more heterogeneous (mean CV of 87 Ϯ 21, 71 Ϯ 18 and 66 Ϯ 13, respectively; P Ͻ 0.01) than in the other two groups of individuals. In contrast, the percentage of CD2
ϩ NK-cells was significantly higher (P Ͻ 0.05) in both groups of patients compared to controls (mean percentage of CD2 ϩ cells of 79 Ϯ 9% in AI and 84 Ϯ 15% in CI/N patients versus 74 Ϯ 11% in controls). Moreover, although CD2 was expressed at variable levels in the different groups of individuals analyzed, the pattern of CD2 expression was more homogeneous in CI/N patients compared to the other groups of individuals (mean CV of 44 Ϯ 13% in CI/N patients versus 64 Ϯ 12% in controls and 60 Ϯ 9% in AI patients; P Ͻ 0.001).
Differences in both CD2 and CD7 expression on CD56
ϩlo NK-cells between normal and pathological samples were due to differences in the relative representation of distinct subsets of NK-cells defined by the pattern of expression of these molecules: CD2 . Differences between groups were not statistically significant except for a more heterogeneous CD16 expression in AI (P ϭ 0.035) and a more homogeneous CD94 expression in CI/N patients (P ϭ 0.001) compared to controls.
P values: Controls versus patients, *P Ͻ 0.05, **P Ͻ 0.01, ***P Ͻ 0.001; AI versus CI/N patients, ϩ P Ͻ 0.05, ϩϩ P Ͻ 0.01, ϩϩϩ P Ͻ 0.001.
CD7
Ϫ/ϩlo NK-cells (Fig. 1) . The majority of CD56 ϩlo NK-cells from normal individuals and AI patients were CD2 Ϫ/ϩlo
/CD7
ϩhi whereas CI/N individuals showed an increased proportion of CD2 ϩhi
Ϫ/ϩlo NK-cells (Table 3 ). In fact, CD2 /L, respectively; P ϭ 0.008).
As shown in Table 1 and illustrated in Fig. 1 , patients with acute infections showed a slightly higher percentage of CD11c ϩ NK-cells (83 Ϯ 11%; P ϭ 0.152) and a lower proportion of CD57 ϩ NK-cells (21 Ϯ 8%; P Ͻ 0.001) in comparison to healthy controls (74 Ϯ 17% and 56 Ϯ 18%, respectively). These differences resulted from a marked increase in the proportion of CD11c
Ϫ NK-cells (63 Ϯ 9% versus 31 Ϯ 14%; P Ͻ 0.001) and a decrease in both CD11c
ϩ (19 Ϯ 10% versus 42 Ϯ 16%; P Ͻ 0.001) and CD11c
ϩ NK-cells (2 Ϯ 2% versus 13 Ϯ 14%; P Ͻ 0.001) ( Table 3 and Fig. 1 ). In addition, among AI patients the intensity of expression of CD11c on CD56
ϩlo NK-cells was higher (mean MFI of 232 Ϯ 105 versus 144 Ϯ 42; P Ͻ 0.05) and the levels of CD57 were lower (MFI of 259 Ϯ 188 versus 554 Ϯ 339; P Ͻ 0.05) than those observed in controls (Table 2) . By contrast, CI/N patients showed significantly higher relative numbers of CD57 ϩ NK-cells (72 Ϯ 16%) compared to controls (56 Ϯ 18%; P Ͻ 0.05), this differences being even more evident in comparison to AI patients (21 Ϯ 8%; P Ͻ 0.001) ( Table 1) . Moreover, although the mean CD57 levels displayed by CD56
ϩlo NK-cells from CI/N patients did not differ significantly from those observed in normal individuals (mean MFI of 653 Ϯ 410 versus 554 Ϯ 339; P Ͼ 0.05), the pattern of CD57 expression was more homogeneous in this group of patients (mean CV of 82 Ϯ 21%) compared to both controls (mean CV of 115 Ϯ 44; P Ͻ 0.05) and AI individuals (mean CV of 113 Ϯ 28%; P Ͻ 0.001) ( Table 2) . CD38 levels were significantly higher and more homogeneously expressed on CD56
ϩlo NKcells from AI patients (MFI of 177 Ϯ 63 and mean CV of 50 Ϯ 9%; P Ͻ 0.001) while lower in CI/N patients (MFI of 51 Ϯ 25; P Ͻ 0.01) in comparison to normal individuals (mean MFI of 85 Ϯ 31 and mean CV of 81 Ϯ 16%) ( Table 2 ). In contrast, CD11b levels were significantly decreased in CD56
ϩlo NK-cells from both groups of patients in comparison to controls (mean MFI of 49 Ϯ 41 in AI and 42 Ϯ 18 in CI/N patients versus 80 Ϯ 38 in controls; P Ͻ 0.01) ( Table 2) .
In normal, as well as in pathological samples, virtually all CD56
ϩlo NK-cells were CD11a ϩhi , the levels of expression of this adhesion molecule being higher in both AI and CI/N patients than in controls (mean MFI of 645 Ϯ 185 in AI and 553 Ϯ 77 in CI/N patients versus 484 Ϯ 53 in controls; P Ͻ 0.05) ( Table 2 ). In addition, CD56
ϩlo NK-cells displayed variable levels of HLA-DR expression ranging from 16 Ϯ 14% HLA-DR ϩ cells in control samples to 30 Ϯ 26% in CI/N (P ϭ 0.2) and 69 Ϯ 12% in AI patients (P Ͻ 0.001). As expected, in this later group of individuals significantly higher levels of HLA-DR molecules per NK-cell were found compared to both normal individuals and CI/N patients (mean MFI of 472 Ϯ 221 versus 76 Ϯ 21 and 80 Ϯ 36, respectively; P Ͻ 0.001).
In a similar way, most CD56 ϩlo NK-cells from both healthy individuals and CI/N patients showed a homogeneous and high CD45RA expression (MFI of 259 Ϯ 88 and 333 Ϯ 116 and mean CV of 34 Ϯ 5% and 43 Ϯ 19%, respectively; P Ͼ 0.05) in the absence of CD45RO (Tables 1 and 2) while CD56 ϩlo NK-cells from AI patients displayed a slightly lower (mean MFI of 189 Ϯ 77, P ϭ 0.2) and more heterogeneous (mean CV of 59 Ϯ 24%; P Ͻ 0.001) CD45RA expression in the presence of an increased percentage of CD45RO ϩ NK-cells (mean of 23 Ϯ 12% versus 5 Ϯ 5% in controls and 7 Ϯ 13% in CI/N patients; P Ͻ 0.001).
Other Markers
Differences between normal individuals and patients concerning the expression of other markers addressed in this studied were less evident (see notes to Tables 1 and 2 ). Accordingly, except for a lower percentage of CD8 ϩ cells (P Ͻ 0.01) and a more heterogeneous expression of CD16 expression (P Ͻ 0.05) among AI individuals, no significant differences were observed as regards the expression of the other antigens analyzed. Interestingly, in 2/15 AI patients and 2/15 CI/N patients (whereas in none of the control individuals) two CD56 ϩlo NK-cell populations were clearly distinguished based on the levels of CD16 expression, the one expressing the lowest levels of CD16 (CD16 ϩlo ) representing between 33 and 72% of total CD16 ϩ /CD56
ϩlo NK-cells. In that concerning the expression of immunoglobulin-like (CD158a and NKB1) and lectin-like (CD94 and CD161) killer receptors, the only statistically significant difference was a more homogeneous CD94 expression on CD56
ϩlo NK-cells from CI/N patients compared to the control group (mean CV of 65 Ϯ 5 and 50 Ϯ 13%, respectively; P Ͻ 0.001).
DISCUSSION
Previous studies have shown that activated NK-cells express a number of molecules that are absent or present at very low levels in nonactivated NK-cells. Accordingly, NK-cells express "de novo" CD69 (9 -14), HLA-DR (9, 10), CD40L (15) , and CD25 and CD132 (16, 17) after activation with different stimuli at the same time they transiently acquire CD45RO (18) . Besides this, NK-cell activation also results in either down or upregulation of different receptors constitutively expressed by resting mature NK-cells. Accordingly, it has been reported that upon in vitro activation, expression of CD2, CD11a/CD18, CD26, CD44, CD54, and CD58 increases (19 -21) , whereas the surface levels of CD7 (22), CD11b-CD11c/CD18 and CD16/TCRzeta chain complex decrease (9, 10, 19, 23, 24, 26) , reactivity for other molecules such as CD8 remaining stable (25) . Activation-related changes on the expression of some other molecules still remain controversial, probably depending on the type and intensity of the stimuli. In this sense, some reports showed a decrease on the expression of CD56 (27) , whereas others observed an increase on the expression of this adhesion molecule (9, 10) ; the effect of NK-cell activation on the expression of other molecules, such as CD62L (28) and CD49a-f (29) , seems also to be stimuli-dependent. In spite of all the information mentioned above, it should be noted that our knowledge on the modulation of the cellular surface phenotypes associated with NK-cell activation is based mostly on in vitro studies and that few data are available on documenting the phenotypic changes that occur after NK-cell activation in vivo.
In the present study, we have analyzed the phenotypic patterns of both normal and reactive NK-cells, using two different in vivo models of NK-cell activation: patients with acute and chronic processes that have been considered to be associated with activation of this leukocyte population. Interestingly, the use of CD2/CD7, CD57/CD11c, CD38/CD11b, and CD11a/HLA-DR double stainings allowed the identification of discrete subsets of NK-cells which are usually present in normal blood that change their relative distribution during both acute and chronic in vivo responses to stimulatory signals, changes in these subsets contributing to explain the different phenotypic patterns observed in the groups here analyzed.
Accordingly, resting mature CD56 ϩlo NKcells, corresponding to the majority of the NKcells present in normal blood, have a CD2 ϩ counterparts (38) . Recently activated NK-cells typically show strong reactivity for CD38 and express high levels of HLA-DR. At that phase, there is also downregulation of CD45RA, a phenomenon that is transiently accompanied by co-expression of CD45RO in variable proportions of NK-cells. CD11a levels are increased, whereas expression of CD11b may be either normal or decreased. Moreover, these NK-cells are CD11c ϩ while they are either negative or dimly positive for CD57.
In patients with chronic infections and tumors, the former NK-cell subset is substantially replaced by chronically activated NK-cells. These cells shown unique phenotypic features, including upregulation of CD2, which becomes homogeneous (CD2 
/CD45RO
Ϫ phenotype.
Interestingly, it should be noted that NK-cells displaying an early-activation phenotype where found in all patients with acute viral infection whereas in only a minor proportion of patients with chronic infections and tumors and none of the normal healthy individuals. Similarly, chronically-activated NK-cells were overrepresented in patients with NK-cell lymphocytosis associated to conditions in which the underlying stimuli persist for a long time, such as chronic infections and neoplastic diseases, although they could also be found at lower numbers in a few percentage of patients with acute infections as well as in normal individuals.
Changes involving other surface molecules occurring after in vivo NK-cell activation included a decrease on the percentage of CD8 ϩ
CD56
ϩlo NK-cells in AI patients, a more heterogeneous CD16 expression on CD56
ϩlo NK-cells in a subgroup of both AI and CI/N patients and a more homogeneous expression of the CD94 lectin-like NK-cell receptor on CD56
ϩlo NK-cells from CI/N patients, while no significant changes were found as regards the expression of other NK-cell receptors analyzed (CD158a, CD161, and NKB1).
Our results not only show that the majority of changes that have been documented upon NK-cell activation in vitro are also reproducible in vivo, but also allow us to establish a dynamic sequence for these immunophenotypic changes, defining the phenotypic profiles that characterize both the early/acute-and late/chronic-phases of NK-cell activation. Curiously, changes that occur at early stages of NK-cell activation mimic those that were previously described for T-cells (36) , with the exception of upregulation of CD2 and downregulation of CD7, which seems to take place at a latter stage during NK-cell activation. In line with that occurring during T-cell activation (39), CD57 expression also behaves as a late activation marker for NK-cells.
In summary, in the present study we show that the pattern of expression of CD2/CD7, CD57/ CD11c, CD38/CD11b, CD45RA/CD45RO, and CD11a/HLA-DR, contribute to the precise identification of blood NK-cell subsets which display immunophenotypic patterns associated with acute/early and chronic/late NK-cell activation. These findings would contribute to a better understanding of the functional role of NK-cells, as well as to establish the basis necessary for distinguishing between normal/reactive and neoplastic NK-cells, in the absence of clonality markers.
